Charles River Laboratories International (CRL)
(Real Time Quote from BATS)
$222.10 USD
+3.86 (1.77%)
Updated Jul 22, 2024 12:00 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Income Statements
Fiscal Year end for Charles River Laboratories International, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 4,129 | 3,976 | 3,540 | 2,924 | 2,621 |
Cost Of Goods | 2,627 | 2,513 | 2,206 | 1,850 | 1,663 |
Gross Profit | 1,503 | 1,463 | 1,335 | 1,074 | 958 |
Selling & Adminstrative & Depr. & Amort Expenses | 885 | 812 | 745 | 641 | 607 |
Income After Depreciation & Amortization | 617 | 651 | 590 | 433 | 351 |
Non-Operating Income | 101 | 31 | -35 | 101 | 14 |
Interest Expense | 137 | 59 | 74 | 86 | 61 |
Pretax Income | 581 | 623 | 481 | 447 | 304 |
Income Taxes | 101 | 130 | 82 | 82 | 50 |
Minority Interest | 6 | 6 | 8 | 1 | 2 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 480 | 493 | 399 | 365 | 254 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 475 | 486 | 391 | 364 | 252 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 931 | 955 | 855 | 668 | 549 |
Depreciation & Amortization (Cash Flow) | 314 | 304 | 266 | 235 | 198 |
Income After Depreciation & Amortization | 617 | 651 | 590 | 433 | 351 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.45 | 51.30 | 51.43 | 50.61 | 49.69 |
Diluted EPS Before Non-Recurring Items | 10.67 | 11.12 | 10.32 | 8.13 | 6.73 |
Diluted Net EPS (GAAP) | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 |
Fiscal Year end for Charles River Laboratories International, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 1,011.56 | 1,013.48 | 1,026.62 | 1,059.94 |
Cost Of Goods | NA | 666.72 | 649.39 | 664.78 | 660.96 |
Gross Profit | NA | 344.84 | 364.09 | 361.84 | 398.98 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 218.87 | 231.16 | 210.34 | 234.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 125.97 | 132.93 | 151.50 | 164.95 |
Non-Operating Income | NA | 8.04 | 109.33 | -4.89 | -1.24 |
Interest Expense | NA | 35.00 | 33.54 | 33.74 | 35.04 |
Pretax Income | NA | 99.01 | 208.71 | 112.87 | 128.66 |
Income Taxes | NA | 24.53 | 19.75 | 24.85 | 29.22 |
Minority Interest | NA | 1.52 | 1.87 | 0.63 | 2.42 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 74.48 | 188.95 | 88.02 | 99.44 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 72.96 | 187.08 | 87.39 | 97.02 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.84 | 51.62 | 51.61 | 51.47 |
Diluted EPS Before Non-Recurring Items | NA | 2.27 | 2.46 | 2.72 | 2.69 |
Diluted Net EPS (GAAP) | NA | 1.30 | 3.63 | 1.69 | 1.89 |